Literature DB >> 10636472

Melatonin administered in the afternoon decreases next-day luteinizing hormone levels in men: lack of antagonism by flumazenil.

R Luboshitzky1, Z Shen-Orr, T Shochat, P Herer, P Lavie.   

Abstract

The role of melatonin in the regulation of human reproduction remains unclear. In the present study, we examined the influence of exogenous melatonin on pulsatile luteinizing hormone (LH), diurnal rhythm of testosterone, and endogenous melatonin profile in six healthy young adult males. To test the hypothesis that the effect of melatonin on LH or testosterone secretory patterns may be mediated through the benzodiazepine-(BNZ) gamma-amino-butyric acid (GABA) receptor complex, a benzodiazepine receptor antagonist (Flumazenil) was administered. The study design comprised four 10-h (4:00 PM-2:00 AM) testing periods. During each experimental period, subjects were given an oral dose of placebo, or 3 mg melatonin or 10 mg flumazenil, at 5:00 PM, in a randomized, double-blind, partially repeated Latin square design in the following combinations: placebo-placebo, placebo-melatonin, flumazenil-placebo, and flumazenil-melatonin. The following day, serum samples were obtained every 20 min between 4:00 PM and 2:00 AM in a controlled light-dark environment for the determination of LH and melatonin levels. Serum testosterone concentrations were determined every 20 min between 7:00 and 8:00 AM and 7:00 and 8:00 PM. A significant decrease in mean serum LH levels (p < 0.02) was observed in the melatonin-treated groups as compared with placebo-flumazenil groups. There was no change in LH pulse frequency, testosterone levels, or in melatonin onset time and amplitude. No additional effect of flumazenil on LH or testosterone levels was observed. These data indicate that an evening melatonin administration decreases the next-day LH secretion in normal adult males without altering testosterone levels or the endogenous nocturnal melatonin secretory pattern. This effect of melatonin is not mediated through the benzodiazepine-GABA receptor complex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10636472     DOI: 10.1385/JMN:12:1:75

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  24 in total

1.  Central gabaergic mechanisms as targets for melatonin activity in brain.

Authors:  R E Rosenstein; D P Cardinali
Journal:  Neurochem Int       Date:  1990       Impact factor: 3.921

2.  Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation.

Authors:  B C Voordouw; R Euser; R E Verdonk; B T Alberda; F H de Jong; A C Drogendijk; B C Fauser; M Cohen
Journal:  J Clin Endocrinol Metab       Date:  1992-01       Impact factor: 5.958

3.  A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol.

Authors:  F Waldhauser; H R Lieberman; H J Lynch; M Waldhauser; K Herkner; H Frisch; H Vierhapper; W Waldhäusl; M Schemper; R J Wurtman
Journal:  Neuroendocrinology       Date:  1987-08       Impact factor: 4.914

4.  Estimating false-positive and false-negative errors in analyses of hormonal pulsatility.

Authors:  E Van Cauter
Journal:  Am J Physiol       Date:  1988-06

5.  Using Ro 15-1788 to investigate the benzodiazepine receptor in vivo: studies on the anticonvulsant and sedative effect of melatonin and the convulsant effect of the benzodiazepine Ro 05-3663.

Authors:  A R Green; D J Nutt; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  The effects of oral melatonin on skin color and on the release of pituitary hormones.

Authors:  J J Nordlund; A B Lerner
Journal:  J Clin Endocrinol Metab       Date:  1977-10       Impact factor: 5.958

7.  Melatonin effect on daytime sleep in men: suppression of EEG low frequency activity and enhancement of spindle frequency activity.

Authors:  D J Dijk; C Roth; H P Landolt; E Werth; M Aeppli; P Achermann; A A Borbély
Journal:  Neurosci Lett       Date:  1995-12-01       Impact factor: 3.046

8.  Improvement of sleep quality in elderly people by controlled-release melatonin.

Authors:  D Garfinkel; M Laudon; D Nof; N Zisapel
Journal:  Lancet       Date:  1995-08-26       Impact factor: 79.321

9.  Testosterone treatment alters melatonin concentrations in male patients with gonadotropin-releasing hormone deficiency.

Authors:  R Luboshitzky; S Lavi; I Thuma; P Lavie
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

10.  Amplification of nocturnal melatonin secretion in women with functional secondary amenorrhoea: relation to endogenous oestrogen concentration.

Authors:  Y Okatani; Y Sagara
Journal:  Clin Endocrinol (Oxf)       Date:  1994-12       Impact factor: 3.478

View more
  3 in total

Review 1.  Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.

Authors:  Frank M C Besag; Michael J Vasey; Kim S J Lao; Ian C K Wong
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

2.  Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262.

Authors:  Daniel F Kripke; Lawrence E Kline; Farhad F Shadan; Arthur Dawson; J Steven Poceta; Jeffrey A Elliott
Journal:  BMC Womens Health       Date:  2006-05-16       Impact factor: 2.809

3.  Beneficial Effects of Melatonin on the In Vitro Maturation of Sheep Oocytes and Its Relation to Melatonin Receptors.

Authors:  Xiuzhi Tian; Feng Wang; Lu Zhang; Changjiu He; Pengyun Ji; Jing Wang; Zhenzhen Zhang; Dongying Lv; Wusiman Abulizi; Xuguang Wang; Zhengxing Lian; Guoshi Liu
Journal:  Int J Mol Sci       Date:  2017-04-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.